New combo therapy shows promise for tough lung cancers
NCT ID NCT04165096
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding another drug to the immunotherapy pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer whose disease got worse after initial treatment. 128 participants received one of three drug combinations. The goal was to see if tumors shrank or disappeared. The trial is now complete, and results will show whether these combinations are safe and effective enough to pursue in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) plus boserolimab, MK-4830, or MK-0482
What this could lead to
If successful, this could point toward a new combination treatment option for people with advanced lung cancer whose disease has progressed after initial immunotherapy.
What could go wrong
This is an early Phase 2 study with only 128 participants, so results may not apply to everyone. The drug combinations may cause side effects or fail to shrink tumors in many patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
Philadelphia, Pennsylvania, 19104, United States
-
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Firenze, 50134, Italy
-
Banner MD Anderson Cancer Center ( Site 0001)
Gilbert, Arizona, 85234, United States
-
Chaim Sheba Medical Center ( Site 0070)
Ramat Gan, 5262000, Israel
-
City of Hope ( Site 0014)
Duarte, California, 91010, United States
-
Cleveland Clinic Main ( Site 0006)
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute ( Site 0002)
Boston, Massachusetts, 02215, United States
-
Dartmouth Hitchcock Medical Center ( Site 0016)
Lebanon, New Hampshire, 03766, United States
-
Georgetown University ( Site 0036)
Washington D.C., District of Columbia, 20007, United States
-
Hospital Universitario Quiron Madrid ( Site 0091)
Pozuelo de Alarcón, Madrid, 28223, Spain
-
ICO L Hospitalet ( Site 0090)
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
IRCCS Ospedale San Raffaele ( Site 0171)
Milan, 20132, Italy
-
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
Hackensack, New Jersey, 07601, United States
-
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary
-
Laura and Isaac Perlmutter Cancer Center ( Site 0034)
New York, New York, 10016, United States
-
Massachusetts General Hospital ( Site 0003)
Boston, Massachusetts, 02114, United States
-
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland, 21237, United States
-
Meir Medical Center ( Site 0071)
Kfar Saba, 4428132, Israel
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Ohio State University Comprehensive Cancer Center ( Site 0015)
Columbus, Ohio, 43210, United States
-
Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
Omaha, Nebraska, 68130, United States
-
Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
Budapest, 1121, Hungary
-
Petz Aladar Megyei Oktato Korhaz ( Site 0062)
Győr, Győr-Moson-Sopron, 9024, Hungary
-
Policlinico Gemelli di Roma ( Site 0174)
Rome, Lazio, 00168, Italy
-
Rabin Medical Center ( Site 0074)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology ( Site 0076)
Haifa, 3109601, Israel
-
Samsung Medical Center ( Site 0082)
Seoul, 06351, South Korea
-
Sanford Cancer Center ( Site 0038)
Sioux Falls, South Dakota, 57104, United States
-
Sanford Fargo Medical Center ( Site 0039)
Fargo, North Dakota, 58102, United States
-
Seoul National University Bundang Hospital ( Site 0081)
Seongnam-si, Kyonggi-do, 13620, South Korea
-
Severance Hospital ( Site 0080)
Seoul, 03722, South Korea
-
Shaare Zedek Medical Center ( Site 0075)
Jerusalem, 9103102, Israel
-
Soroka Medical Center ( Site 0072)
Beersheba, 8457108, Israel
-
Sourasky Medical Center ( Site 0077)
Tel Aviv, 6423906, Israel
-
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
Koszalin, West Pomeranian Voivodeship, 75-581, Poland
-
The University of Texas MD Anderson Cancer Center ( Site 0009)
Houston, Texas, 77030, United States
-
UCSF Medical Center at Mission Bay ( Site 0007)
San Francisco, California, 94158, United States
-
University of Kentucky Markey Cancer Center ( Site 0019)
Lexington, Kentucky, 40536-0293, United States
-
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomeranian Voivodeship, 80-952, Poland